Loading
PACIFIC-2 asked whether starting durvalumab during chemoradiotherapy, rather than after it, would help people with stage III lung cancer; it did not, so the sequence established by the original PACIFIC trial stands.
PACIFIC established durvalumab given after chemoradiotherapy as the standard for unresectable stage III non-small-cell lung cancer. PACIFIC-2 tested the more aggressive schedule of starting durvalumab at the same time as platinum-based chemoradiotherapy and continuing it afterwards, against placebo, in 328 patients. The primary endpoint was progression-free survival.
The trial did not show a statistically significant improvement in progression-free survival, and more patients in the durvalumab arm stopped treatment early for adverse events. Consolidation after chemoradiotherapy therefore remains the way durvalumab is used in this setting.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
328 enrolled.
95% CI 9.5 to 16.9 · 95% CI 7.5 to 16.6
Source| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Progression-free survival (registry results)primary | Durvalumab + concurrent chemoradiotherapy | - | 13.8 months | 0.85 (0.647 to 1.123) | 0.247 | link |
| Placebo + concurrent chemoradiotherapy | - | 9.4 months |
Shares Durvalumab, AstraZeneca, Cisplatin, Immune checkpoint inhibitors and the tag subtype-trials.
Shares AstraZeneca, Lung cancer (all types), Non-small-cell lung cancer and the tag subtype-trials.
Shares Carboplatin, Lung cancer (all types), Immune checkpoint inhibitors, Non-small-cell lung cancer and the tag subtype-trials.
Shares Cisplatin, Immune checkpoint inhibitors and the tag subtype-trials.
Shares Cisplatin, Immune checkpoint inhibitors and the tag subtype-trials.
Shares Cisplatin, Immune checkpoint inhibitors and the tag subtype-trials.
Shares Cisplatin, Carboplatin and the tag subtype-trials.
Shares Lung cancer (all types), Non-small-cell lung cancer and the tag subtype-trials.